影像診斷相關的聯盟趨勢:條件、契約內容

本報告提供全球影像診斷領域的企業聯盟的締結趨勢和其內容相關分析，彙整近幾年的企業聯盟趨勢和特徵，平均交易條件，代表性交易案例，大型製藥企業的契約動向，近幾年的聯盟交易一覽和其明細等資訊，為您概述為以下內容。

摘要整理

第1章 簡介

第2章 影像診斷相關的各種契約趨勢

• 簡介
• 過去的聯盟趨勢
• 最活躍的經營者
• 影像診斷相關的聯盟:各類型契約
• 影像診斷相關的聯盟:各治療領域
• 聯盟的交易條件
• 契約總額
• 預付款金
• 里程金金
• 權利金比率

第3章 主要影像診斷相關的交易

• 簡介
• 主要契約:各契約金額

第4章 最活躍的經營者

• 簡介
• 最活躍的經營者
• 最活躍的經營者的簡介

第5章 影像診斷相關的契約交易名錄

• 簡介
• 影像診斷相關的契約交易名錄

第6章 影像診斷相關的交易:各技術

第7章 聯盟資源中心

• 網路夥伴合作
• 合作夥伴活動
• 相關資料

附錄

Description

Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the diagnostic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of diagnostic deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 2087 diagnostic deals announced since 2016 including financial terms where available including links to online deal records of actual diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of diagnostic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in diagnostic dealmaking since 2016.

Chapter 3 provides an overview of the leading diagnostic deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in diagnostic dealmaking with a brief summary followed by a comprehensive listing of diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of diagnostic deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of diagnostic partnering deals signed and announced since Jan 2016. The chapter is organized by specific diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in diagnostic deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse diagnostic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.

Diagnostic Collaboration and Licensing Deals includes:

• Trends in diagnostic dealmaking in the biopharma industry
• Directory of diagnostic deal records covering pharmaceutical and biotechnology
• The leading diagnostic deals by value
• Most active diagnostic licensing dealmakers
• Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse diagnostic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in diagnostic dealmaking

• 2.1. Introduction
• 2.2. Diagnostic deals over the years
• 2.3. Most active diagnostic dealmakers
• 2.4. Diagnostic deals by deal type
• 2.5. Diagnostic deals by therapy area
• 2.6. Diagnostic deals by industry sector
• 2.7. Deal terms for diagnostic deals
  • 2.7.1 Diagnostic deals headline values
  • 2.7.2 Diagnostic deal upfront payments
  • 2.7.3 Diagnostic deal milestone payments
  • 2.7.4 Diagnostic royalty rates

Chapter 3 - Leading diagnostic deals

• 3.1. Introduction
• 3.2. Top diagnostic deals by value

Chapter 4 - Most active diagnostic dealmakers

• 4.1. Introduction
• 4.2. Most active diagnostic dealmakers
• 4.3. Most active diagnostic deals company profiles

Chapter 5 - Diagnostic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Diagnostic contracts dealmaking directory

Chapter 6 - Diagnostic dealmaking by technology type

• Deal directory
• Deal directory - Diagnostic deals by company A-Z
• Deal directory - Diagnostic deals by deal type
• Deal directory - Diagnostic deals by therapy area
• Deal type definitions
• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering
•  

Table of figures

• Figure 1: Diagnostic deals since 2016
• Figure 2: Active diagnostic dealmaking activity - 2016 - 2023
• Figure 3: Diagnostic deals by deal type since 2016
• Figure 4: Diagnostic deals by therapy area since 2016
• Figure 5: Diagnostic deals by industry sector since 2016
• Figure 6: Diagnostic deals with a headline value
• Figure 7: Diagnostic deals with an upfront value
• Figure 8: Diagnostic deals with a milestone value
• Figure 9: Diagnostic deals with a royalty rate value
• Figure 10: Top diagnostic deals by value since 2016
• Figure 11: Most active diagnostic dealmakers 2016 - 2023
• Figure 12: Diagnostic deals by technology type since 2016